Comparison
Argireline vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
616204-22-9
204656-20-2
Molecular weight
888.99 g/mol
3751 g/mol
Half-life
no data
13 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1